Social Europe

politics, economy and employment & labour

  • Themes
    • European digital sphere
    • Recovery and resilience
  • Publications
    • Books
    • Dossiers
    • Occasional Papers
    • Research Essays
    • Brexit Paper Series
  • Podcast
  • Videos
  • Newsletter

Challenging patents key to make Covid-19 vaccine work for all

Kateřina Konečná 2nd July 2020

Finding a vaccine against the coronavirus is a biochemical challenge. Ensuring universal access to it, however, is a political choice.

Covid-19 vaccine, pharamaceutical companies, patents
Kateřina Konečná

Since the outbreak of Covid-19, the search for effective treatments and a vaccine to stem the spread of the pandemic has generated much political debate and many headlines. The race to find a vaccine has been particularly fierce among big pharmaceutical companies competing to become the first to commercialise it on the market. According to the New York Times, more than 135 vaccines are being developed, with two reaching the phase of large-scale efficacy tests—the final stage before deployment.

These companies are prime recipients of billions of euro in public money to support research and development to find a vaccine. The European Commission, through its Coronavirus Global Response, has raised €7.4 billion towards this end.

A major motivation for many of these efforts is the desire to find a cure for the pandemic that has infected millions of people around the world, killed hundreds of thousands, and disproportionately affected the most vulnerable. This however is only part of the picture.

First-mover advantage

Big pharmaceutical corporates are aggressively seeking what in the business world is known as ‘first-mover advantage’. The risk is that the first to develop an effective Covid-19 vaccine files for a patent which could make it sole supplier. Shareholders are pouring billions into these companies, in the hope of reaping big dividends.

Our job is keeping you informed!


Subscribe to our free newsletter and stay up to date with the latest Social Europe content.


We will never send you spam and you can unsubscribe anytime.

Thank you!

Please check your inbox and click on the link in the confirmation email to complete your newsletter subscription.

.

Such exclusivity usually applies for 20 years but companies are known to manipulate the system to secure extensions. They can make minor changes, including to the colour of a pill, to renew a patent—changes which may not have benefits for patients but are sufficient to extend control over the drug and who can thus have access to it.

Crucially, patents allow businesses to set prices—extremely high prices for first-mover pharmaceutical companies able to exploit the absence of alternatives in the market. This artificial inflation drives up costs for our public healthcare systems and increases the proportion of public money going to multinational companies, many based abroad, turning access to lifesaving drugs from a universal right into a privilege. Private health has already flourished in some European Union countries at the behest of the ‘troika’ (of the commission, the European Central Bank and the International Monetary Fund) supervising bailout programmes.

The current arrangements mean that those who are able to pay for drugs will obtain privileged access to a Covid-19 vaccine. Those unable to pay will be left stranded. We have seen how this story ends. An unjust and unequal system will mean millions of lost lives.

Universal access

But it needn’t be this way. Alternatives exist. Putting the public good above private interests means respecting the right to cure in public healthcare systems with universal access.

I am greatly inspired by the actions of the freedom-fighter, and South Africa’s first democratically-elected president, Nelson Mandela, who in the 1990s challenged the international patents system and the predatory behaviour of pharmaceutical companies. Mandela accused big companies of exploitation by charging exorbitant prices for HIV-AIDS drugs. He and his successor circumvented international patent rules to allow manufacturers to copy expensive drugs, delivering lower costs and saving lives.


We need your support


Social Europe is an independent publisher and we believe in freely available content. For this model to be sustainable, however, we depend on the solidarity of our readers. Become a Social Europe member for less than 5 Euro per month and help us produce more articles, podcasts and videos. Thank you very much for your support!

Become a Social Europe Member

Multinational corporations, backed by the US government, took the South African government to court, with Mandela as first defendant. Following international uproar, supported by a vibrant grassroots campaign, the drug companies however dropped the case, marking a huge victory for the right to cure.

Guarantees needed

The European Commission president, Ursula von der Leyen, has said that a Covid-19 vaccine would be universally accessible. But she has given no assurances as to how that would happen.

We need guarantees. The current system is broken. We cannot afford to lose more lives because of some companies’ desire to treat our health as a profitable commodity.

A progressive alliance across Europe, in which I take part, has launched a campaign to demand, first, that the EU condition research grants to pharmaceutical companies on universal access and, secondly, that the discriminatory and unjust patenting system be reformed, drawing on alternatives such as a universal patent pool.

A Covid-19 vaccine must be a public good. We have a right to cure.

Kateřina Konečná

Kateřina Konečná (KSČM, Czechia) is an MEP with the Left group in the European Parliament (GUE/NGL).

Home ・ Politics ・ Challenging patents key to make Covid-19 vaccine work for all

Most Popular Posts

schools,Sweden,Swedish,voucher,choice Sweden’s schools: Milton Friedman’s wet dreamLisa Pelling
world order,Russia,China,Europe,United States,US The coming world orderMarc Saxer
south working,remote work ‘South working’: the future of remote workAntonio Aloisi and Luisa Corazza
Russia,Putin,assets,oligarchs Seizing the assets of Russian oligarchsBranko Milanovic
Russians,support,war,Ukraine Why do Russians support the war against Ukraine?Svetlana Erpyleva

Most Recent Posts

Sakharov,nuclear,Khrushchev Unhappy birthday, Andrei SakharovNina L Khrushcheva
Gazprom,Putin,Nordstream,Putin,Schröder How the public loses out when politicians cash inKatharina Pistor
defence,europe,spending Ukraine and Europe’s defence spendingValerio Alfonso Bruno and Adriano Cozzolino
North Atlantic Treaty Organization,NATO,Ukraine The Ukraine war and NATO’s renewed credibilityPaul Rogers
transnational list,European constituency,European elections,European public sphere A European constituency for a European public sphereDomènec Ruiz Devesa

Other Social Europe Publications

The transatlantic relationship
Women and the coronavirus crisis
RE No. 12: Why No Economic Democracy in Sweden?
US election 2020
Corporate taxation in a globalised era

Eurofound advertisement

Living and working in Europe 2021

The Covid-19 pandemic continued to be a defining force in 2021, and Eurofound continued its work of examining and recording the many and diverse impacts across the EU. Living and working in Europe 2021 provides a snapshot of the changes to employment, work and living conditions in Europe. It also summarises the agency’s findings on issues such as gender equality in employment, wealth inequality and labour shortages. These will have a significant bearing on recovery from the pandemic, resilience in the face of the war in Ukraine and a successful transition to a green and digital future.


AVAILABLE HERE

Foundation for European Progressive Studies Advertisement

EU Care Atlas: a new interactive data map showing how care deficits affect the gender earnings gap in the EU

Browse through the EU Care Atlas, a new interactive data map to help uncover what the statistics are often hiding: how care deficits directly feed into the gender earnings gap.

While attention is often focused on the gender pay gap (13%), the EU Care Atlas brings to light the more worrisome and complex picture of women’s economic inequalities. The pay gap is just one of three main elements that explain the overall earnings gap, which is estimated at 36.7%. The EU Care Atlas illustrates the urgent need to look beyond the pay gap and understand the interplay between the overall earnings gap and care imbalances.


BROWSE THROUGH THE MAP

Hans Böckler Stiftung Advertisement

Towards a new Minimum Wage Policy in Germany and Europe: WSI minimum wage report 2022

The past year has seen a much higher political profile for the issue of minimum wages, not only in Germany, which has seen fresh initiatives to tackle low pay, but also in those many other countries in Europe that have embarked on substantial and sustained increases in statutory minimum wages. One key benchmark in determining what should count as an adequate minimum wage is the threshold of 60 per cent of the median wage, a ratio that has also played a role in the European Commission's proposals for an EU-level policy on minimum wages. This year's WSI Minimum Wage Report highlights the feasibility of achieving minimum wages that meet this criterion, given the political will. And with an increase to 12 euro per hour planned for autumn 2022, Germany might now find itself promoted from laggard to minimum-wage trailblazer.


FREE DOWNLOAD

ETUI advertisement

Bilan social / Social policy in the EU: state of play 2021 and perspectives

The new edition of the Bilan social 2021, co-produced by the European Social Observatory (OSE) and the European Trade Union Institute (ETUI), reveals that while EU social policy-making took a blow in 2020, 2021 was guided by the re-emerging social aspirations of the European Commission and the launch of several important initiatives. Against the background of Covid-19, climate change and the debate on the future of Europe, the French presidency of the Council of the EU and the von der Leyen commission must now be closely scrutinised by EU citizens and social stakeholders.


AVAILABLE HERE

About Social Europe

Our Mission

Article Submission

Membership

Advertisements

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641

Social Europe Archives

Search Social Europe

Themes Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

Follow us on social media

Follow us on Facebook

Follow us on Twitter

Follow us on LinkedIn

Follow us on YouTube